MCID: PGM005
MIFTS: 39

Pigment Dispersion Syndrome

Categories: Rare diseases, Eye diseases

Aliases & Classifications for Pigment Dispersion Syndrome

MalaCards integrated aliases for Pigment Dispersion Syndrome:

Name: Pigment Dispersion Syndrome 12 14 69
Glaucoma-Related Pigment Dispersion Syndrome 12 42
Pigment-Dispersion Type Glaucoma 12
Pigment-Dispersion Syndrome 50
Glaucoma, Open-Angle 69

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases


External Ids:

Disease Ontology 12 DOID:0060680
MeSH 42 C563184

Summaries for Pigment Dispersion Syndrome

NIH Rare Diseases : 50 pigment-dispersion syndrome is an eye disorder that occurs when pigment granules that normally adhere to the back of the iris (the colored part of the eye) flake off into the clear fluid produced by the eye (aqueous humor). these pigment granules may flow towards the drainage canals of the eye, slowly clogging them and raising the pressure within the eye (intraocular pressure or iop). this rise in eye pressure can cause damage to the optic nerve (the nerve in the back of the eye that carries visual images to the brain). if the optic nerve becomes damaged, pigment-dispersion syndrome becomes pigmentary glaucoma. this happens in about 30% of cases. pigment-dispersion syndrome commonly presents between the second and fourth decades, which is earlier than other types of glaucoma. while men and women are affected in equal numbers, men develop pigmentary glaucoma up to 3 times more often than women.myopia (nearsightedness) appears to be an important risk factor in the development of pigment-dispersion syndrome and is present in up to 80% of affected individuals. the condition may be sporadic or follow an autosomal dominant pattern of inheritance with reduced penetrance . at least one genelocus on chromosome 7 has been identified. pigment-dispersion syndrome can be treated with eye drops or other medications. in some cases, laser surgery may be performed.  last updated: 5/16/2015

MalaCards based summary : Pigment Dispersion Syndrome, also known as glaucoma-related pigment dispersion syndrome, is related to retinitis and breast-ovarian cancer, familial, 2. An important gene associated with Pigment Dispersion Syndrome is LOXL1 (Lysyl Oxidase Like 1), and among its related pathways/superpathways are Degradation of the extracellular matrix and Direct p53 effectors. The drugs Travoprost and Apraclonidine have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and brain, and related phenotypes are pigmentation and reproductive system

Disease Ontology : 12 An eye disease characterized by slit-like depigmented areas of the iris with up to 50% of patients going on to develop gluacoma.

Wikipedia : 72 Pigment dispersion syndrome (PDS) is an affliction of the eye that can lead to a form of glaucoma known... more...

Related Diseases for Pigment Dispersion Syndrome

Diseases related to Pigment Dispersion Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 14)
id Related Disease Score Top Affiliating Genes
1 retinitis 10.1
2 breast-ovarian cancer, familial, 2 9.7 ADAMTS18 PITX2
3 exfoliation syndrome 9.7
4 cataract 9.7
5 open-angle glaucoma 9.7
6 horner's syndrome 9.7
7 coloboma 9.7
8 uveitis 9.7
9 psoriasis 9.7
10 ocular hypertension 9.7
11 anterior uveitis 9.7
12 koro 9.6 ADAMTS18 COL18A1
13 skin granular cell tumor 9.6 LOXL1 PITX2
14 autosomal dominant nocturnal frontal lobe epilepsy 2 7.5 ADAMTS18 COL18A1 GPDS1 LOXL1 PITX2 TYRP1

Comorbidity relations with Pigment Dispersion Syndrome via Phenotypic Disease Network (PDN):


Anatomical Narrow Angle Borderline Glaucoma Glaucoma 1, Open Angle, F
Hypertension, Essential Ocular Hypotension

Graphical network of the top 20 diseases related to Pigment Dispersion Syndrome:



Diseases related to Pigment Dispersion Syndrome

Symptoms & Phenotypes for Pigment Dispersion Syndrome

MGI Mouse Phenotypes related to Pigment Dispersion Syndrome:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 pigmentation MP:0001186 9.33 PITX2 TYRP1 COL18A1
2 reproductive system MP:0005389 9.26 ADAMTS18 LOXL1 PITX2 TYRP1
3 vision/eye MP:0005391 8.92 ADAMTS18 COL18A1 PITX2 TYRP1

Drugs & Therapeutics for Pigment Dispersion Syndrome

Drugs for Pigment Dispersion Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 203)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Travoprost Approved Phase 4,Phase 3,Phase 2,Phase 1 157283-68-6 5282226
2
Apraclonidine Approved Phase 4 66711-21-5 2216
3
Ephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2 299-42-3 9294
4
Latanoprost Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 130209-82-4 5282380 5311221
5
Pseudoephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2 90-82-4 7028
6
Dorzolamide Approved Phase 4,Phase 3,Phase 2 120279-96-1 3154 5284549
7
Timolol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 26839-75-8 33624 5478
8
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
9
Brinzolamide Approved Phase 4,Phase 3,Phase 2 138890-62-7 68844
10
Bimatoprost Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 155206-00-1 5311027
11
Sorbitol Approved Phase 4 50-70-4 5780
12
Pilocarpine Approved Phase 4 54-71-7, 92-13-7 5910
13
Dipivefrin Approved Phase 4,Phase 3 52365-63-6 3105
14
Bevacizumab Approved, Investigational Phase 4 216974-75-3
15
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
16
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
17
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
18
Maleic acid Experimental Phase 4,Phase 3,Phase 1,Phase 2 110-16-7 444266
19 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1
21 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
22 Brimonidine Tartrate Phase 4,Phase 3,Phase 2,Phase 1 70359-46-5
23 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Nasal Decongestants Phase 4,Phase 3,Phase 1,Phase 2
25 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Respiratory System Agents Phase 4,Phase 3,Phase 1,Phase 2
27 Tetrahydrozoline Phase 4,Phase 3,Phase 2,Phase 1
28 Vasoconstrictor Agents Phase 4,Phase 3,Phase 1,Phase 2
29 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
31 Adrenergic beta-Antagonists Phase 4,Phase 3,Phase 2,Phase 1
32 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Carbonic Anhydrase Inhibitors Phase 4,Phase 3,Phase 2
34 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Ketorolac Tromethamine Phase 4
36 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1
37 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3,Phase 2,Phase 1
38 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Phase 1
39 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
40 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
41 Mitomycins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Alkylating Agents Phase 4,Phase 3,Phase 2
43 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
44 Lubricant Eye Drops Phase 4,Phase 3,Phase 2
45 Cloprostenol Phase 4,Phase 3
46 Contraceptive Agents Phase 4,Phase 3
47 Luteolytic Agents Phase 4,Phase 3
48 Cathartics Phase 4
49 Gastrointestinal Agents Phase 4
50 Laxatives Phase 4

Interventional clinical trials:

(show top 50) (show all 641)

id Name Status NCT ID Phase Drugs
1 Open-angle Glaucoma Subjects on One Ocular Hypotensive Medication Randomized to Treatment With Two Trabecular Micro-bypass Stents or Selective Laser Trabeculoplasty Unknown status NCT01444105 Phase 4
2 Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Randomized to Treatment With One or Two Trabecular Micro-bypass Stents in Conjunction With Cataract Surgery Unknown status NCT01455467 Phase 4
3 A Study of the iStent in Combo With Cataract Surgery in Newly Diagnosed Open Angle Glaucoma or OH Patients. Unknown status NCT00326066 Phase 4
4 Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost Unknown status NCT01443988 Phase 4 Travoprost
5 Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost Unknown status NCT01444040 Phase 4 Travoprost
6 A Study of the Glaukos Trabecular Micro-bypass Stent in Open Angle Glaucoma Subjects 1 Stent Versus 2 Unknown status NCT00326079 Phase 4
7 Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With Two iStents Unknown status NCT01252888 Phase 4
8 Micropulse Laser Trabeculoplasty Versus Selective Laser Trabeculoplasty for Treatment of Open Angle Glaucoma Unknown status NCT01956942 Phase 4
9 Prospective Evaluation of Open-Angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two iStents Unknown status NCT01252862 Phase 4
10 Purpose of This Study is to Evaluate the Safety and Efficacy of One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma Subjects Unknown status NCT01252849 Phase 4
11 The Impact of Topical Prostaglandins on the Biomechanical Properties of the Cornea in Patients With Open Angle Glaucoma Unknown status NCT02388360 Phase 4 topical prostaglandin analogs
12 Efficacy and Safety of Three Different Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma Unknown status NCT01580254 Phase 4 IOPIZE© Latanoprost eyedrops;GALAXIA© Latanoprost eyedrops;Latanoprost RATIOPHARM© latanoprost eyedrops
13 PASCAL Trabeculoplasty Unknown status NCT00804323 Phase 4
14 Prospective, Randomized, Controlled Study to Assess Efficacy,Safety, and Tolerability of SLT vs. PLT in Patients With POAG Unknown status NCT02231515 Phase 4
15 Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients Unknown status NCT02053298 Phase 4 Timolol & Dorzolamide
16 The Laser in Pseudoexfoliation (LIP) Study Unknown status NCT01704989 Phase 4 Prostagladin
17 Choroidal Thickness in Glaucoma Patients and Healthy Controls Unknown status NCT01293474 Phase 4
18 Reproducibility of RNFL Circle Scans With ART-Function of Heidelberg Spectralis SD-OCT Software Version 5.3 Unknown status NCT01299233 Phase 4
19 Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves Unknown status NCT01883856 Phase 4
20 An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More Completed NCT01979913 Phase 4 Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis
21 A Study of the Glaukos Trabecular Micro-Bypass Stent in Refractory Open Angle Glaucoma Subjects Completed NCT00326040 Phase 4
22 A Study of the Trabecular Micro-Bypass Stent in Combination With Cataract Surgery in Open Angle Glaucoma Subjects. Completed NCT00326014 Phase 4
23 24-hour Intraocular Pressure (IOP) Control With Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combination in Open-angle Glaucoma Completed NCT00397241 Phase 4 Drug: dorzolamide/timolol;Drug: latanoprost/timolol;dorzolamide/timolol and latanoprost;placebo (artificial tears)
24 Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®) Completed NCT01464424 Phase 4 Travoprost 0.004% ophthalmic solution;Bimatoprost 0.01% ophthalmic solution
25 Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED) Completed NCT00545064 Phase 4 dorzolamide hydrochloride (+) timolol maleate
26 Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00759239 Phase 4 Travoprost 0.004% / Timolol maleate 0.5%;Travoprost 0.004% / Timolol maleate 0.5%
27 A Prospective, Unmasked Evaluation of the iStent in Patients With Primary Open-Angle Glaucoma Completed NCT00911924 Phase 4
28 Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG) Completed NCT00913029 Phase 4 latanoprost/timolol
29 A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Completed NCT00527592 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
30 A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma Completed NCT00887029 Phase 4 DuoTrav (travoprost-timolol ophthalmic drops);Xalacom (latanoprost-timolol ophthalmic drops)
31 Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG) Completed NCT00698945 Phase 4 Istalol and Optive;Alphagan
32 Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed NCT01978600 Phase 4 Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension;Timolol Maleate 0.5%
33 Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP) Completed NCT01162603 Phase 4 TAFLUPROST 0.0015% EYEDROPS;LATANOPROST 0.005% EYEDROPS
34 Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution Completed NCT02325518 Phase 4 Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension;Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution;Subject's habitual PGA monotherapy
35 Examination of Ocular Surface Effects With Administration of Travatan Z and XALATAN Completed NCT00798759 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
36 Comparison of Ex-PRESSTM Mini Glaucoma Shunt to Trabeculectomy in Subjects With Open Angle Glaucoma Completed NCT00444080 Phase 4
37 A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons Completed NCT01853085 Phase 4 Bimatoprost Ophthalmic Solution
38 Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00966940 Phase 4 Travoprost 0.004% ophthalmic solution (TRAVATAN);Tafluprost 0.0015% ophthalmic solution
39 Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00372827 Phase 4 Brinzolamide 1% added to Travoprost 0.004%
40 Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension Completed NCT00763061 Phase 4 Travoprost 0.004% Ophthalmic Solution (Travatan);Timolol 0.5% Ophthalmic Solution (Timoptic)
41 A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma Completed NCT00647101 Phase 4 Latanoprost
42 Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00822081 Phase 4 brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination;dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination;brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.;dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.
43 Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00822055 Phase 4 brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination;dorzolamide hcl 2%/timolol maleate 0.5% fixed combination;brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy;dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy
44 Comparison Of Trabeculectomy Versus The Ex-PRESS Miniature Glaucoma Device In The Same Patient: A Prospective Randomized Study Completed NCT00698438 Phase 4
45 Efficacy And Safety of Pneumatic Trabeculoplasty Completed NCT01540331 Phase 4
46 Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00804648 Phase 4 Timolol Maleate in Sorbate;Timolol hemihydrate;Timolol maleate gel forming solution
47 Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension. Completed NCT00140062 Phase 4 latanoprost 0.005% (Xalatan)
48 Non Interventional Study in Patients With Open Angle Glaucoma and/or Ocular Hypertension Treated With XALATAN® Completed NCT00486252 Phase 4
49 Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure Completed NCT02003391 Phase 4 Beta-blocker monotherapy;Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution
50 Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy. Completed NCT00801437 Phase 4 Xalacom

Search NIH Clinical Center for Pigment Dispersion Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: glaucoma-related pigment dispersion syndrome

Genetic Tests for Pigment Dispersion Syndrome

Anatomical Context for Pigment Dispersion Syndrome

MalaCards organs/tissues related to Pigment Dispersion Syndrome:

39
Eye, Testes, Brain, Endothelial, Bone, Retina

Publications for Pigment Dispersion Syndrome

Articles related to Pigment Dispersion Syndrome:

(show top 50) (show all 114)
id Title Authors Year
1
Pigment dispersion syndrome andA pigmentary glaucoma after secondary sulcus transscleral fixation of single-piece foldableA posterior chamber intraocular lensesA inA Chinese aphakic patients. ( 28602325 )
2017
2
Corneal collagen crosslinking and pigment dispersion syndrome. ( 28410728 )
2017
3
Pigment dispersion syndrome associated with spontaneous subluxation of crystalline lens. ( 28298869 )
2017
4
A Case of Bilateral Pigment Dispersion Syndrome Following Many Years of Uninterrupted Treatment With Atropine 1% for Bilateral Congenital Cataracts. ( 28671922 )
2017
5
Update on pigment dispersion syndrome and pigmentary glaucoma. ( 27898469 )
2016
6
What's in a Gene? Pseudoexfoliation Syndrome and Pigment Dispersion Syndrome in the Same Patient. ( 26933430 )
2016
7
A Severe Case of Pigmentary Glaucoma in a Child With a Family History of Pigment Dispersion Syndrome. ( 27175994 )
2016
8
Pigment Dispersion Syndrome Progression to Pigmentary Glaucoma in a Latin American Population. ( 26997839 )
2015
9
Pigment dispersion syndrome associated with optic nerve melanocytoma. ( 26008928 )
2015
10
Comparison of Ganglion Cell and Retinal Nerve Fiber Layer Thickness in Pigment Dispersion Syndrome, Pigmentary Glaucoma, and Healthy Subjects with Spectral-domain OCT. ( 26291741 )
2015
11
A 10-Year Follow-up to Determine the Effect of YAG Laser Iridotomy on the Natural History of Pigment Dispersion Syndrome: A Randomized Clinical Trial. ( 25188224 )
2014
12
Common sequence variants in the LOXL1 gene in pigment dispersion syndrome and pigmentary glaucoma. ( 24739284 )
2014
13
Longitudinal stability of the diurnal rhythm of intraocular pressure in subjects with healthy eyes, ocular hypertension and pigment dispersion syndrome. ( 25316067 )
2014
14
Iris coloboma in one eye and pigment dispersion syndrome in the fellow eye. ( 23704455 )
2013
15
Secondary pigmentary glaucoma in patients with underlying primary pigment dispersion syndrome. ( 23569351 )
2013
16
Reverse pupillary block associated with pigment dispersion syndrome after in-the-bag intraocular lens implantation. ( 24140374 )
2013
17
The genetics of pigment dispersion syndrome and pigmentary glaucoma. ( 23218808 )
2013
18
Multispectral diagnostic imaging of the iris in pigment dispersion syndrome. ( 21423031 )
2012
19
Visual and IOP outcomes after PRK in pigment dispersion syndrome. ( 21972450 )
2011
20
Biometric analysis of pigment dispersion syndrome using anterior segment optical coherence tomography. ( 21531465 )
2011
21
Pigment dispersion syndrome masquerading as acute anterior uveitis. ( 21595531 )
2011
22
Pupil capture of intraocular lens in vitrectomized eye with primary pigment dispersion syndrome. ( 21333885 )
2011
23
The concave iris in pigment dispersion syndrome. ( 20801519 )
2011
24
Secondary pigment dispersion syndrome with single-piece acrylic IOL. ( 20692578 )
2010
25
Pigment dispersion syndrome: An atypical presentation. ( 20606874 )
2010
26
Pigment dispersion syndrome patients do not have larger-than-normal irides. ( 20164802 )
2010
27
The role of the lens in pigment dispersion syndrome. ( 22785540 )
2010
28
Aqueous humor dynamics in pigment dispersion syndrome. ( 20837793 )
2010
29
The role of the lens in pigment dispersion syndrome. ( 21117571 )
2010
30
Pigment dispersion syndrome associated with intraocular lens implantation: a new surgical technique. ( 21151331 )
2010
31
Solving intraocular lens-related pigment dispersion syndrome with repositioning of primary sulcus implanted single-piece IOL in the capsular bag. ( 19631135 )
2009
32
Clinical characteristics of pigment dispersion syndrome in Chinese patients. ( 18989347 )
2009
33
Ultrastructural analysis of the pigment dispersion syndrome in DBA/2J mice. ( 19641932 )
2009
34
Anterior segment imaging using optical coherence tomography in atypical pigment dispersion syndrome. ( 19789610 )
2009
35
A comparison of interocular differences in patients with pigment dispersion syndrome. ( 19142127 )
2009
36
Temporal evolution of intraocular pressure elevation after pupillary dilation in pigment dispersion syndrome. ( 19295368 )
2009
37
Exfoliation syndrome and exfoliation glaucoma-associated LOXL1 variations are not involved in pigment dispersion syndrome and pigmentary glaucoma. ( 18618003 )
2008
38
Secondary pigment dispersion syndrome after in-the-bag AcrySof intraocular lens SN60AT implantation. ( 18219355 )
2008
39
Annular and central heavy pigment deposition on the posterior lens capsule in the pigment dispersion syndrome: pigment deposition on the posterior lens capsule in the pigment dispersion syndrome. ( 17972014 )
2008
40
Pigment dispersion syndrome and pigmentary glaucoma--a major review. ( 19278484 )
2008
41
Infrared imaging technique may help demonstrate iris transillumination defects in blacks who show other pigment dispersion syndrome clinical signs. ( 17700286 )
2007
42
Two novel deletions (array CGH findings) in pigment dispersion syndrome. ( 18161622 )
2007
43
Phenotypic variability of pigment dispersion syndrome in children. ( 17210864 )
2007
44
Histologic findings in pigment dispersion syndrome and pigmentary glaucoma. ( 16633228 )
2006
45
Ultrasound biomicroscopy in asymmetric pigment dispersion syndrome and pigmentary glaucoma. ( 17102004 )
2006
46
Atypical pigment dispersion syndrome in a child. ( 15059719 )
2004
47
Outcomes of laser in situ keratomileusis in patients with pigment dispersion syndrome. ( 14967276 )
2004
48
Pigment dispersion syndrome and pigmentary glaucoma. ( 14989503 )
2004
49
Retinal nerve fiber layer loss in pigment dispersion syndrome. ( 15506611 )
2004
50
Case from the aerospace medicine residents' teaching file. Pigment dispersion syndrome. ( 12546305 )
2003

Variations for Pigment Dispersion Syndrome

Expression for Pigment Dispersion Syndrome

Search GEO for disease gene expression data for Pigment Dispersion Syndrome.

Pathways for Pigment Dispersion Syndrome

Pathways related to Pigment Dispersion Syndrome according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.45 ADAMTS18 COL18A1 LOXL1
2 11.08 COL18A1 TYRP1

GO Terms for Pigment Dispersion Syndrome

Cellular components related to Pigment Dispersion Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 basement membrane GO:0005604 8.96 COL18A1 LOXL1
2 proteinaceous extracellular matrix GO:0005578 8.8 ADAMTS18 COL18A1 LOXL1

Biological processes related to Pigment Dispersion Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular matrix organization GO:0030198 8.96 COL18A1 LOXL1
2 animal organ morphogenesis GO:0009887 8.62 COL18A1 PITX2

Molecular functions related to Pigment Dispersion Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 copper ion binding GO:0005507 8.62 LOXL1 TYRP1

Sources for Pigment Dispersion Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....